Cantone, A;
Dicorato, MM;
Porcari, A;
(2025)
The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy.
Current Cardiology Reports
, 27
(1)
, Article 153. 10.1007/s11886-025-02308-6.
Preview |
Text
The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy.pdf - Published Version Download (1MB) | Preview |
Abstract
Purpose of Review: This review aims to provide an updated overview of the clinical management of heart failure and comorbidities in transthyretin amyloid cardiomyopathy (ATTR-CM). We sought to address key unanswered questions and current uncertainties regarding treatment response, prognosis, and optimization of care in this complex population. Recent Findings: Once considered rare, ATTR-CM is now increasingly recognized due to greater awareness and the possibility of non-invasive diagnosis. Patients are often identified at earlier stages, with lower mortality than historically observed. Disease-modifying therapies with proven efficacy in randomized trials are now available, yet many patients experience disease progression. In real-world practice, ATTR-CM patients are typically older and have multiple cardiac and extracardiac comorbidities, often representing exclusion criteria of clinical trials, which may influence treatment response and efficacy. Summary: Modern management of ATTR-CM should integrate heart failure treatment with tailored approaches to comorbidity care. Earlier diagnosis, real-world evidence, and strategies for patients outside trial populations will be essential to improve prognosis and guide future research.
| Type: | Article |
|---|---|
| Title: | The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1007/s11886-025-02308-6 |
| Publisher version: | https://doi.org/10.1007/s11886-025-02308-6 |
| Language: | English |
| Additional information: | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| Keywords: | Clinical management, Comorbidities, Disease-modifying treatments, Heart failure, Prognosis, Transthyretin amyloid cardiomyopathy, Humans, Amyloid Neuropathies, Familial, Comorbidity, Heart Failure, Cardiomyopathies, Prognosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10218898 |
Archive Staff Only
 |
View Item |
